A micro RNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses, which functions in RNA silencing and post-transcriptional regulation of gene expression.
Encoded by eukaryotic nuclear DNA in plants and animals and by viral DNA in certain viruses whose genome is based on DNA, miRNAs function via base-pairing with complementary sequences within mRNA molecules. As a result, these mRNA molecules are silenced by one or more of the following processes: 1) cleavage of the mRNA strand into two pieces, 2) destabilization of the mRNA through shortening of its poly(A) tail, and 3) less efficient translation of the mRNA into proteins by ribosomes. miRNAs resemble the small interfering RNAs (siRNAs) of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. The human genome may encode over 1000 miRNAs, which are abundant in many mammalian cell types and appear to target about 60% of the genes of humans and other mammals.
miRNAs are well conserved in both plants and animals, and are thought to be a vital and evolutionarily ancient component of genetic regulation. While core components of the microRNA pathway are conserved between plants and animals, miRNA repertoires in the two kingdoms appear to have emerged independently with different primary modes of action. Plant miRNAs usually have near-perfect pairing with their mRNA targets, which induces gene repression through cleavage of the target transcripts. In contrast, animal miRNAs are able to recognize their target mRNAs by using as little as 6–8 nucleotides (the seed region) at the 5' end of the miRNA, which is not enough pairing to induce cleavage of the target mRNAs. Combinatorial regulation is a feature of miRNA regulation in animals. A given miRNA may have hundreds of different mRNA targets, and a given target might be regulated by multiple miRNAs.
The first miRNA was discovered in the early 1990s. However, miRNAs were not recognized as a distinct class of biological regulators until the early 2000s. Since then, miRNA research has revealed different sets of miRNAs expressed in different cell types and tissues and has revealed multiple roles for miRNAs in plant and animal development and in many other biological processes. Aberrant expression of miRNAs has been implicated in numerous disease states, and miRNA-based therapies are under investigation.
Estimates of the average number of unique messenger RNAs that are targets for repression by a typical microRNA vary, depending on the method used to make the estimate, but several approaches show that mammalian miRNAs can have many unique targets. For example, an analysis of the miRNAs highly conserved in vertebrate animals shows that each of these miRNAs has, on average, roughly 400 conserved targets. Likewise, experiments show that a single miRNA can reduce the stability of hundreds of unique messenger RNAs, and other experiments show that a single miRNA may repress the production of hundreds of proteins, but that this repression often is relatively mild (less than 2-fold).
- History 1
- Nomenclature 2
- Transcription 3.1
- Nuclear processing 3.2
- Nuclear export 3.3
- Cytoplasmic processing 3.4
- Biogenesis in plants 3.5
The RNA-induced silencing complex 4
- Mode of silencing and regulatory loops 4.1
- miRNA turnover 5
- Cellular functions 6
- Evolution 7
- Experimental detection and manipulation of miRNA 8
- Inherited diseases 9.1
- Cancer 9.2
- DNA repair and cancer 9.3
Heart disease 9.4
- miRNA-712 9.4.1
- Gene Origin 9.4.2
- Mechanism 9.4.3
- Human Homolog microRNA-205 9.4.4
- Kidney disease 9.5
Nervous system 9.6
- Alcoholism 9.6.1
- Obesity 9.7
- Non-coding RNAs 10
- Viruses 11
- Target prediction 12
- See also 13
- References 14
- Bibliography 15
- External links 16
The first miRNA was discovered in 1993 by Victor Ambros, Rosalind Lee and Rhonda Feinbaum during a study of the lin-4 gene, which was known to control the timing of C. elegans larval development by repressing the lin-14 gene. When they isolated the lin-4 gene, they found that instead of producing an mRNA encoding a protein, it produced short noncoding RNAs, one of which was a ~22-nucleotide RNA that contained sequences partially complementary to multiple sequences in the 3' UTR of the lin-14 mRNA. This complementarity was proposed to inhibit the translation of the lin-14 mRNA into the LIN-14 protein. At the time, the lin-4 small RNA was thought to be a nematode idiosyncrasy. Only in 2000 was a second small RNA characterized: let-7 RNA, which represses lin-41 to promote a later developmental transition in C. elegans. The let-7 RNA was soon found to be conserved in many species, leading to the suggestion that let-7 RNA and additional "small temporal RNAs" might regulate the timing of development in diverse animals, including humans. A year later, the lin-4 and let-7 RNAs were found to be part of a very large class of small RNAs present in C. elegans, Drosophila and human cells. The many newly discovered RNAs of this class resembled the lin-4 and let-7 RNAs, except their expression patterns were usually inconsistent with a role in regulating the timing of development, which suggested that most might function in other types of regulatory pathways. At this point, researchers started using the term “microRNA” to refer to this class of small regulatory RNAs.
Under a standard nomenclature system, names are assigned to experimentally confirmed miRNAs before publication of their discovery. The prefix "miR" is followed by a dash and a number, the latter often indicating order of naming. For example, miR-124 was named and likely discovered prior to miR-456. A capitalized "miR-" refers to the mature form of the miRNA, while the uncapitalized "mir-" refers to the pre-miRNA and the pri-miRNA, and "MIR" refers to the gene that encodes them. miRNAs with nearly identical sequences except for one or two nucleotides are annotated with an additional lower case letter. For example, miR-124a is closely related to miR-124b. Pre-miRNAs, pri-miRNAs and genes that lead to 100% identical mature miRNAs but that are located at different places in the genome are indicated with an additional dash-number suffix. For example, the pre-miRNAs hsa-mir-194-1 and hsa-mir-194-2 lead to an identical mature miRNA (hsa-miR-194) but are from genes located in different regions of the genome. Species of origin is designated with a three-letter prefix, e.g., hsa-miR-124 is a human (Homo sapiens) miRNA and oar-miR-124 is a sheep (Ovis aries) miRNA. Other common prefixes include 'v' for viral (miRNA encoded by a viral genome) and 'd' for Drosophila miRNA (a fruit fly commonly studied in genetic research). When two mature microRNAs originate from opposite arms of the same pre-miRNA and are found in roughly similar amounts, they are denoted with a -3p or -5p suffix. (In the past, this distinction was also made with 's' (sense) and 'as' (antisense)). However, the mature microRNA found from one arm of the hairpin is usually much more abundant than that found from the other arm, in which case, an asterisk following the name indicates the mature species found at low levels from the opposite arm of a hairpin. For example, miR-124 and miR-124* share a pre-miRNA hairpin, but much more miR-124 is found in the cell.
MicroRNAs are produced from either their own genes or from introns. A video of this process can be found here.
The majority of the characterized miRNA genes are intergenic or oriented antisense to neighboring genes and are therefore suspected to be transcribed as independent units. However, in some cases a microRNA gene is transcribed together with its host gene; this provides a means for coupled regulation of miRNA and protein-coding gene. As much as 40% of miRNA genes may lie in the introns of protein and non-protein coding genes or even in exons of long nonprotein-coding transcripts. These are usually, though not exclusively, found in a sense orientation, and thus usually are regulated together with their host genes. Other miRNA genes showing a common promoter include the 42-48% of all miRNAs originating from polycistronic units containing multiple discrete loops from which mature miRNAs are processed, although this does not necessarily mean the mature miRNAs of a family will be homologous in structure and function. The promoters mentioned have been shown to have some similarities in their motifs to promoters of other genes transcribed by RNA polymerase II such as protein coding genes. The DNA template is not the final word on mature miRNA production: 6% of human miRNAs show RNA editing (IsomiRs), the site-specific modification of RNA sequences to yield products different from those encoded by their DNA. This increases the diversity and scope of miRNA action beyond that implicated from the genome alone.
miRNA genes are usually transcribed by RNA polymerase II (Pol II). The polymerase often binds to a promoter found near the DNA sequence encoding what will become the hairpin loop of the pre-miRNA. The resulting transcript is capped with a specially modified nucleotide at the 5’ end, polyadenylated with multiple adenosines (a poly(A) tail), and spliced. Animal miRNAs are initially transcribed as part of one arm of an ∼80 nucleotide RNA stem-loop that in turn forms part of a several hundred nucleotides long miRNA precursor termed a primary miRNA (pri-miRNA)s. When a stem-loop precursor is found in the 3' UTR, a transcript may serve as a pri-miRNA and a mRNA. RNA polymerase III (Pol III) transcribes some miRNAs, especially those with upstream Alu sequences, transfer RNAs (tRNAs), and mammalian wide interspersed repeat (MWIR) promoter units.
A single pri-miRNA may contain from one to six miRNA precursors. These hairpin loop structures are composed of about 70 nucleotides each. Each hairpin is flanked by sequences necessary for efficient processing. The double-stranded RNA structure of the hairpins in a pri-miRNA is recognized by a nuclear protein known as Drosha, a protein that cuts RNA, to form the "Microprocessor" complex. In this complex, DGCR8 orients the catalytic RNase III domain of Drosha to liberate hairpins from pri-miRNAs by cleaving RNA about eleven nucleotides from the hairpin base (one helical dsRNA turn into the stem). The product resulting has a two-nucleotide overhang at its 3’ end; it has 3' hydroxyl and 5' phosphate groups. It is often termed as a pre-miRNA (precursor-miRNA). Sequence motifs downstream of the pre-miRNA that are important for efficient processing have been identified.
Pre-miRNAs that are spliced directly out of introns, bypassing the Microprocessor complex, are known as "Mirtrons." Originally thought to exist only in Drosophila and C. elegans, mirtrons have now been found in mammals.
Perhaps as many as 16% of pre-miRNAs may be altered through nuclear RNA editing. Most commonly, enzymes known as adenosine deaminases acting on RNA (ADARs) catalyze adenosine to inosine (A to I) transitions. RNA editing can halt nuclear processing (for example, of pri-miR-142, leading to degradation by the ribonuclease Tudor-SN) and alter downstream processes including cytoplasmic miRNA processing and target specificity (e.g., by changing the seed region of miR-376 in the central nervous system).
Pre-miRNA hairpins are exported out of the nucleus in a process involving the nucleocytoplasmic shuttler Exportin-5. This protein, a member of the karyopherin family, recognizes a two-nucleotide overhang left by the RNase III enzyme Drosha at the 3' end of the pre-miRNA hairpin. Exportin-5-mediated transport to the cytoplasm is energy-dependent, using GTP bound to the Ran protein.
In the cytoplasm, the pre-miRNA hairpin is cleaved by the RNase III enzyme Dicer. This endoribonuclease interacts with 5' and 3' ends of the hairpin and cuts away the loop joining the 3' and 5' arms, yielding an imperfect miRNA:miRNA* duplex about 22 nucleotides in length. Overall hairpin length and loop size influence the efficiency of Dicer processing, and the imperfect nature of the miRNA:miRNA* pairing also affects cleavage. Some of the G-rich pre-miRNAs can potentially adopt the G-quadruplex structure as an alternative to the canonical stem-loop structure. For example, human pre-miRNA 92b adopts a G-quadruplex structure which is resistant to the Dicer mediated cleavage in the cytoplasm. Although either strand of the duplex may potentially act as a functional miRNA, only one strand is usually incorporated into the RNA-induced silencing complex (RISC) where the miRNA and its mRNA target interact.
Biogenesis in plants
miRNA biogenesis in plants differs from animal biogenesis mainly in the steps of nuclear processing and export. Instead of being cleaved by two different enzymes, once inside and once outside the nucleus, both cleavages of the plant miRNA is performed by a Dicer homolog, called Dicer-like1 (DL1). DL1 is only expressed in the nucleus of plant cells, which indicates that both reactions take place inside the nucleus. Before plant miRNA:miRNA* duplexes are transported out of the nucleus, its 3' overhangs are methylated by a RNA methyltransferaseprotein called Hua-Enhancer1 (HEN1). The duplex is then transported out of the nucleus to the cytoplasm by a protein called Hasty (HST), an Exportin 5 homolog, where they disassemble and the mature miRNA is incorporated into the RISC.
The RNA-induced silencing complex
The mature miRNA is part of an active RNA-induced silencing complex (RISC) containing Dicer and many associated proteins. RISC is also known as a microRNA ribonucleoprotein complex (miRNP); RISC with incorporated miRNA is sometimes referred to as "miRISC."
Dicer processing of the pre-miRNA is thought to be coupled with unwinding of the duplex. Generally, only one strand is incorporated into the miRISC, selected on the basis of its thermodynamic instability and weaker base-pairing relative to the other strand. The position of the stem-loop may also influence strand choice. The other strand, called the passenger strand due to its lower levels in the steady state, is denoted with an asterisk (*) and is normally degraded. In some cases, both strands of the duplex are viable and become functional miRNA that target different mRNA populations.
Members of the Argonaute (Ago) protein family are central to RISC function. Argonautes are needed for miRNA-induced silencing and contain two conserved RNA binding domains: a PAZ domain that can bind the single stranded 3’ end of the mature miRNA and a PIWI domain that structurally resembles ribonuclease-H and functions to interact with the 5’ end of the guide strand. They bind the mature miRNA and orient it for interaction with a target mRNA. Some argonautes, for example human Ago2, cleave target transcripts directly; argonautes may also recruit additional proteins to achieve translational repression. The human genome encodes eight argonaute proteins divided by sequence similarities into two families: AGO (with four members present in all mammalian cells and called E1F2C/hAgo in humans), and PIWI (found in the germ line and hematopoietic stem cells).
Additional RISC components include TRBP [human immunodeficiency virus (HIV) transactivating response RNA (TAR) binding protein], PACT (protein activator of the interferon induced protein kinase), the SMN complex, fragile X mental retardation protein (FMRP), Tudor staphylococcal nuclease-domain-containing protein (Tudor-SN), the putative DNA helicase MOV10, and the RNA recognition motif containing protein TNRC6B.
Mode of silencing and regulatory loops
Gene silencing may occur either via mRNA degradation or preventing mRNA from being translated. For example, miR16 contains a sequence complementary to the AU-rich element found in the 3'UTR of many unstable mRNAs, such as TNF alpha or GM-CSF. It has been demonstrated that if there is complete complementation between the miRNA and target mRNA sequence, Ago2 can cleave the mRNA and lead to direct mRNA degradation. Yet, if there isn't complete complementation the silencing is achieved by preventing translation. The relation of miRNA and its target mRNA(s) can be based on the simple negative regulation of a target mRNA, but it seems that a common scenario is the use of a “coherent feed-forward loop” (Fig. 1C), “mutual negative feedback loop” (also termed double negative loop) and “positive feedback/feed-forward loop”. It was also demonstrated that some miRNAs work as buffers of random gene expression changes arising due to stochastic events in transcription, translation and protein stability. Such regulation is typically achieved by the virtue of negative feedback loops or incoherent feed-forward loop uncoupling protein output from mRNA transcription.
Turnover of mature miRNA is needed for rapid changes in miRNA expression profiles. During miRNA maturation in the cytoplasm, uptake by the Argonaute protein is thought to stabilize the guide strand, while the opposite (* or "passenger") strand is preferentially destroyed. In what has been called a "Use it or lose it" strategy, Argonaute may preferentially retain miRNAs with many targets over miRNAs with few or no targets, leading to degradation of the non-targeting molecules.
Decay of mature miRNAs in Caenorhabditis elegans is mediated by the 5´-to-3´ exoribonuclease XRN2, also known as Rat1p. In plants, SDN (small RNA degrading nuclease) family members degrade miRNAs in the opposite (3'-to-5') direction. Similar enzymes are encoded in animal genomes, but their roles have not yet been described.
Several miRNA modifications affect miRNA stability. As indicated by work in the model organism Arabidopsis thaliana (thale cress), mature plant miRNAs appear to be stabilized by the addition of methyl moieties at the 3' end. The 2'-O-conjugated methyl groups block the addition of uracil (U) residues by uridyltransferase enzymes, a modification that may be associated with miRNA degradation. However, uridylation may also protect some miRNAs; the consequences of this modification are incompletely understood. Uridylation of some animal miRNAs has also been reported. Both plant and animal miRNAs may be altered by addition of adenine (A) residues to the 3' end of the miRNA. An extra A added to the end of mammalian miR-122, a liver-enriched miRNA important in Hepatitis C, stabilizes the molecule, and plant miRNAs ending with an adenine residue have slower decay rates.
The function of miRNAs appears to be in gene regulation. For that purpose, a miRNA is complementary to a part of one or more messenger RNAs (mRNAs). Animal miRNAs are usually complementary to a site in the 3' UTR whereas plant miRNAs are usually complementary to coding regions of mRNAs. Perfect or near perfect base pairing with the target RNA promotes cleavage of the RNA. This is the primary mode of plant miRNAs. In animals miRNAs more often have only partly the right sequence of nucleotides to bond with the target mRNA. The match-ups are imperfect. For partially complementary microRNAs to recognise their targets, nucleotides 2–7 of the miRNA (its 'seed region') still have to be perfectly complementary. Animal miRNAs inhibit protein translation of the target mRNA (this exists in plants as well but is less common). MicroRNAs that are partially complementary to a target can also speed up deadenylation, causing mRNAs to be degraded sooner. While degradation of miRNA-targeted mRNA is well documented, whether or not translational repression is accomplished through mRNA degradation, translational inhibition, or a combination of the two is hotly debated. Recent work on miR-430 in zebrafish, as well as on bantam-miRNA and miR-9 in Drosophila cultured cells, shows that translational repression is caused by the disruption of translation initiation, independent of mRNA deadenylation.
Nine mechanisms of miRNA action are described and assembled in a unified mathematical model:
- Cap-40S initiation inhibition;
- 60S Ribosomal unit joining inhibition;
- Elongation inhibition;
- Ribosome drop-off (premature termination);
- Co-translational nascent protein degradation;
- Sequestration in P-bodies;
- mRNA Decay (destabilisation);
- mRNA Cleavage;
- Transcriptional inhibition through microRNA-mediated chromatin reorganization following by gene silencing.
It is often impossible to discern these mechanisms using the experimental data about stationary reaction rates. Nevertheless, they are differentiated in dynamics and have different kinetic signatures.
Unlike plant microRNAs, the animal microRNAs target a diverse set of genes. However, genes involved in functions common to all cells, such as gene expression, have relatively fewer microRNA target sites and seem to be under selection to avoid targeting by microRNAs.
dsRNA can also activate gene expression, a mechanism that has been termed "small RNA-induced gene activation" or RNAa. dsRNAs targeting gene promoters can induce potent transcriptional activation of associated genes. This was demonstrated in human cells using synthetic dsRNAs termed small activating RNAs (saRNAs), but has also been demonstrated for endogenous microRNA.
Interactions between microRNAs and complementary sequences on genes and even pseudogenes that share sequence homology are thought to be a back channel of communication regulating expression levels between paralogous genes. Given the name "competing endogenous RNAs" (ceRNAs), these microRNAs bind to "microRNA response elements" on genes and pseudogenes and may provide another explanation for the persistence of non-coding DNA.
MicroRNAs are significant phylogenetic markers because of their astonishingly low rate of evolution. MicroRNAs origin as a regulatory mechanism developed from previous RNAi machinery which was initially used as a defense against exogenous genetic material such as viruses. Their origin may have permitted the development of morphological innovation, and by making gene expression more specific and 'fine-tunable', permitted the genesis of complex organs and perhaps, ultimately, complex life. Indeed, rapid bursts of morphological innovation are generally associated with a high rate of microRNA accumulation.
New microRNAs are created in multiple different ways. Novel microRNAs can originate from the random formation of hairpins in "non-coding" sections of DNA (i.e. introns or intergene regions), but also by the duplication and modification of existing microRNAs. MicroRNAs can also form from inverted duplications of protein-coding sequences, which allows for the creation of a foldback hairpin structure. The rate of evolution (i.e. nucleotide substitution) in recently originated microRNAs is comparable to that elsewhere in the non-coding DNA, implying evolution by neutral drift; however, older microRNAs have a much lower rate of change (often less than one substitution per hundred million years), suggesting that once a microRNA gains a function it undergoes extreme purifying selection. Additionally, different regions within an miRNA gene seem to be under different evolutionary pressures, where regions that are vital for processing and function have much higher levels of conservation. At this point, a microRNA is rarely lost from an animal's genome, although microRNAs that are more recently derived (and thus presumably non-functional) are frequently lost. In Arabidopsis thaliana, the net flux of miRNA genes has been predicted to be between 1.2 and 3.3 genes per million years. This makes them a valuable phylogenetic marker, and they are being looked upon as a possible solution to such outstanding phylogenetic problems as the relationships of arthropods.
MicroRNAs feature in the
- The miRBase database
- The miRNA Blog
- miR2Disease, a manually curated database documenting known relationships between miRNA dysregulation and human disease.
- semirna, Web application to search for microRNAs in a plant genome.
- miRandola: Extracellular Circulating microRNAs Database.
- MirOB: MicroRNA targets database and data analysis and dataviz tool.
- miRNA definition and classification: Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T (2003). "A uniform system for microRNA annotation". RNA 9 (3): 277–279.
- Discovery of lin-4, the first miRNA to be discovered: Lee RC, Feinbaum RL, Ambros V (1993). "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14". Cell 75 (5): 843–854.
- Ambros, V (Sep 16, 2004). "The functions of animal microRNAs". Nature 431 (7006): 350–5.
- Bartel, DP (Jan 23, 2004). "MicroRNAs: genomics, biogenesis, mechanism, and function". Cell 116 (2): 281–97.
- Bartel DP (January 2009). "MicroRNAs: target recognition and regulatory functions". Cell 136 (2): 215–33.
- Fabian, MR; Sonenberg, N; Filipowicz, W (2010). "Regulation of mRNA translation and stability by microRNAs". Annual review of biochemistry 79: 351–79.
- miRNAs in the miRBaseHomo sapiens at Manchester University
- Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z; Avniel; Karov; Aharonov; Gilad; Barad; Barzilai; Einat; Einav; Meiri; Sharon; Spector; Bentwich (July 2005). "Identification of hundreds of conserved and nonconserved human microRNAs". Nat. Genet. 37 (7): 766–70.
- Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP; Lau; Weinstein; Abdelhakim; Yekta; Rhoades; Burge; Bartel (April 2003). "The microRNAs of Caenorhabditis elegans". Genes Dev. 17 (8): 991–1008.
- Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T; Rauhut; Yalcin; Meyer; Lendeckel; Tuschl (April 2002). "Identification of tissue-specific microRNAs from mouse". Curr. Biol. 12 (9): 735–9.
- Lewis BP, Burge CB, Bartel DP (2005). "Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets". Cell 120 (1): 15–20.
- Friedman RC, Farh KK, Burge CB, Bartel DP; Farh; Burge; Bartel (January 2009). "Most mammalian mRNAs are conserved targets of microRNAs". Genome Res. 19 (1): 92–105.
- Axtell, MJ; Bartel, DP (Jun 2005). "Antiquity of microRNAs and their targets in land plants". The Plant cell 17 (6): 1658–73.
- Tanzer A, Stadler PF; Stadler (May 2004). "Molecular evolution of a microRNA cluster". J. Mol. Biol. 339 (2): 327–35.
- Chen, Kevin; Rajewsky, Nikolaus (2007). "The evolution of gene regulation by transcription factors and microRNAs". Nature Reviews Genetics 8 (2): 93–103.
- Lee CT, Risom T, Strauss WM; Risom; Strauss (April 2007). "Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny". DNA Cell Biol. 26 (4): 209–18.
- Peterson, KJ; Dietrich, MR; McPeek, MA (Jul 2009). "MicroRNAs and metazoan macroevolution: insights into canalization, complexity, and the Cambrian explosion". BioEssays : news and reviews in molecular, cellular and developmental biology 31 (7): 736–47.
- Shabalina SA, Koonin EV; Koonin (October 2008). "Origins and evolution of eukaryotic RNA interference". Trends in Ecology and Evolution. 10 (10): 578–587.
- Axtell, MJ; Westholm, JO; Lai, EC (2011). "Vive la différence: biogenesis and evolution of microRNAs in plants and animals". Genome Biology 12 (4): 221.
- Jones-Rhoades, MW; Bartel, DP; Bartel, B (2006). "MicroRNAS and their regulatory roles in plants". Annual review of plant biology 57: 19–53.
- Lewis BP, Shih IH, Jones-Rhoades M, Bartel DP, Burge CB (2003). "Prediction of Mammalian MicroRNA Targets". Cell 115 (7): 787–798.
- Ellwanger DC, Büttner FA, Mewes HW, Stümpflen V (2011). "The sufficient minimal set of miRNA seed types". Bioinformatics 27 (10): 1346–50.
- Rajewsky, Nikolaus (2006). "microRNA target predictions in animals". Nature Genetics 38 (6s): S8–S13.
- Krek, Azra; Grün, Dominic; Poy, Matthew N; Wolf, Rachel; Rosenberg, Lauren; Epstein, Eric J; MacMenamin, Philip; da Piedade, Isabelle; Gunsalus, Kristin C; Stoffel, Markus; Rajewsky, Nikolaus (May 2005). "Combinatorial microRNA target predictions". Nature Genetics 37 (5): 495–500.
- Lee RC, Feinbaum RL, Ambros V; Feinbaum; Ambros (December 1993). "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14". Cell 75 (5): 843–54.
- Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G; Slack; Basson; Pasquinelli; Bettinger; Rougvie; Horvitz; Ruvkun (February 2000). "The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans". Nature 403 (6772): 901–6.
- Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G; Reinhart; Slack; Martindale; Kuroda; Maller; Hayward; Ball; Degnan; Müller; Spring; Srinivasan; Fishman; Finnerty; Corbo; Levine; Leahy; Davidson; Ruvkun (November 2000). "Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA". Nature 408 (6808): 86–9.
- Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T; Rauhut; Lendeckel; Tuschl (October 2001). "Identification of novel genes coding for small expressed RNAs". Science 294 (5543): 853–8.
- Lau NC, Lim LP, Weinstein EG, Bartel DP; Lim; Weinstein; Bartel (October 2001). "An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans". Science 294 (5543): 858–62.
- Lee RC, Ambros V; Ambros (October 2001). "An extensive class of small RNAs in Caenorhabditis elegans". Science 294 (5543): 862–4.
- Wienholds, E; Kloosterman, WP; Miska, E; Alvarez-Saavedra, E; Berezikov, E; de Bruijn, E; Horvitz, HR; Kauppinen, S; Plasterk, RH (Jul 8, 2005). "MicroRNA expression in zebrafish embryonic development". Science 309 (5732): 310–1.
- Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM; Hipfner; Stark; Russell; Cohen (April 2003). "bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila". Cell 113 (1): 25–36.
- Cuellar TL, McManus MT; McManus (December 2005). "MicroRNAs and endocrine biology". J. Endocrinol. 187 (3): 327–32.
- Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M; Eliasson; Krutzfeldt; Kuwajima; Ma; MacDonald; Pfeffer; Tuschl; Rajewsky; Rorsman; Stoffel (November 2004). "A pancreatic islet-specific microRNA regulates insulin secretion". Nature 432 (7014): 226–30.
- Chen CZ, Li L, Lodish HF, Bartel DP; Li; Lodish; Bartel (January 2004). "MicroRNAs modulate hematopoietic lineage differentiation". Science 303 (5654): 83–6.
- Wilfred BR, Wang WX, Nelson PT; Wang; Nelson (July 2007). "Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways". Mol. Genet. Metab. 91 (3): 209–17.
- Harfe BD, McManus MT, Mansfield JH, Hornstein E, Tabin CJ; McManus; Mansfield; Hornstein; Tabin (August 2005). "The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb". Proc. Natl. Acad. Sci. U.S.A. 102 (31): 10898–903.
- Trang P, Weidhaas JB, Slack FJ; Weidhaas; Slack (December 2008). "MicroRNAs as potential cancer therapeutics". Oncogene. 27 Suppl 2: S52–7.
- Li C, Feng Y, Coukos G, Zhang L; Feng; Coukos; Zhang (December 2009). "Therapeutic microRNA strategies in human cancer". AAPS J 11 (4): 747–57.
- Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F; Greco; Ivan; Capogrossi; Martelli (January 2010). "microRNA: emerging therapeutic targets in acute ischemic diseases". Pharmacol. Ther. 125 (1): 92–104.
- Hydbring, Per; Badalian-Very, Gayane (August 2013). "Clinical applications of microRNAs". F1000Research 2.
- Thomson DW, Bracken CP, Goodall GJ; Bracken; Goodall (September 2011). "Experimental strategies for microRNA target identification". Nucleic Acids Res. 39 (16): 6845–53.
- Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM; Lau; Garrett-Engele; Grimson; Schelter; Castle; Bartel; Linsley; Johnson (February 2005). "Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs". Nature 433 (7027): 769–73.
- Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N; Schwanhäusser; Thierfelder; Fang; Khanin; Rajewsky (September 2008). "Widespread changes in protein synthesis induced by microRNAs". Nature 455 (7209): 58–63.
- Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP; Villén; Shin; Camargo; Gygi; Bartel (September 2008). "The impact of microRNAs on protein output". Nature 455 (7209): 64–71.
- Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T; Bartel; Bartel; Burge; Carrington; Chen; Dreyfuss; Eddy; Griffiths-Jones; Marshall; Matzke; Ruvkun; Tuschl (March 2003). "A uniform system for microRNA annotation". RNA 9 (3): 277–9.
- Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ; Grocock; Van Dongen; Bateman; Enright (January 2006). "miRBase: microRNA sequences, targets and gene nomenclature". Nucleic Acids Res. 34 (Database issue): D140–4.
- Wright, MW; Bruford, EA (Jan 2011). "Naming 'junk': human non-protein coding RNA (ncRNA) gene nomenclature". Human genomics 5 (2): 90–8.
- Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN; Kim; Han; Yeom; Lee; Baek; Kim (October 2004). "MicroRNA genes are transcribed by RNA polymerase II". EMBO J. 23 (20): 4051–60.
- Mraz M, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky M, Verner J, Doubek M, Brychtova Y, Trbusek M, Hampl A, Mayer J, Pospisilova S (March 2012). "MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia". Blood 119 (9): 2110–2113.
- Lisse TS, Chun RF, Rieger S, Adams JS, Hewison M (June 2013). "Vitamin D activation of functionally distinct regulatory miRNAs in primary human osteoblasts". J Bone Miner Res. 28 (6): 1478–14788.
- Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A; Griffiths-Jones; Ashurst; Bradley (October 2004). "Identification of mammalian microRNA host genes and transcription units". Genome Res. 14 (10A): 1902–10.
- Cai X, Hagedorn CH, Cullen BR; Hagedorn; Cullen (December 2004). "Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs". RNA 10 (12): 1957–66.
- Weber MJ (January 2005). "New human and mouse microRNA genes found by homology search". FEBS J. 272 (1): 59–73.
- Kim YK, Kim VN; Kim (February 2007). "Processing of intronic microRNAs". EMBO J. 26 (3): 775–83.
- Baskerville S, Bartel DP; Bartel (March 2005). "Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes". RNA 11 (3): 241–7.
- Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H; Landgraf; Lithwick; Elefant; Pfeffer; Aravin; Brownstein; Tuschl; Margalit (2005). "Clustering and conservation patterns of human microRNAs". Nucleic Acids Res. 33 (8): 2697–706.
- Zhou X, Ruan J, Wang G, Zhang W; Ruan; Wang; Zhang (March 2007). "Characterization and identification of microRNA core promoters in four model species". PLoS Comput. Biol. 3 (3): e37.
- Faller M, Guo F; Guo (November 2008). "MicroRNA biogenesis: there's more than one way to skin a cat". Biochim. Biophys. Acta 1779 (11): 663–7.
- Lee, Y; Ahn, C; Han, J; Choi, H; Kim, J; Yim, J; Lee, J; Provost, P; Rådmark, O; Kim, S; Kim, VN (25 September 2003). "The nuclear RNase III Drosha initiates microRNA processing.". Nature 425 (6956): 415–9.
- Gregory RI, Chendrimada TP, Shiekhattar R; Chendrimada; Shiekhattar (2006). "MicroRNA biogenesis: isolation and characterization of the microprocessor complex". Methods Mol. Biol. 342: 33–47.
- Han, J; Lee, Y; Yeom, KH; Kim, YK; Jin, H; Kim, VN (15 December 2004). "The Drosha-DGCR8 complex in primary microRNA processing.". Genes & Development 18 (24): 3016–27.
- Han, J; Lee, Y; Yeom, KH; Nam, JW; Heo, I; Rhee, JK; Sohn, SY; Cho, Y; Zhang, BT; Kim, VN (2 June 2006). "Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex.". Cell 125 (5): 887–901.
- Conrad, Thomas; Annalisa, Marsico; Gehre, Maja; Ørom, Ulf (Oct 23, 2014). "Microprocessor activity controls differential miRNA biogenesis In Vivo.". Cell Reports 9 (2): 542–554.
- Auyeung, Vincent; Igor, Ulitsky; McGeary, SE; Bartel, DP (Feb 14, 2013). "Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing.". Cell 152 (4): 844–858.
- Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC; Chung; Willis; Cuppen; Lai (October 2007). "Mammalian mirtron genes". Mol. Cell 28 (2): 328–36.
- Kawahara Y, Megraw M, Kreider E, Iizasa H, Valente L, Hatzigeorgiou AG, Nishikura K; Megraw; Kreider; Iizasa; Valente; Hatzigeorgiou; Nishikura (September 2008). "Frequency and fate of microRNA editing in human brain". Nucleic Acids Res. 36 (16): 5270–80.
- Winter J, Jung S, Keller S, Gregory RI, Diederichs S; Jung; Keller; Gregory; Diederichs (March 2009). "Many roads to maturity: microRNA biogenesis pathways and their regulation". Nat. Cell Biol. 11 (3): 228–34.
- Ohman M (October 2007). "A-to-I editing challenger or ally to the microRNA process". Biochimie 89 (10): 1171–6.
- Murchison EP, Hannon GJ; Hannon (June 2004). "miRNAs on the move: miRNA biogenesis and the RNAi machinery". Curr. Opin. Cell Biol. 16 (3): 223–9.
- Lund E, Dahlberg JE; Dahlberg (2006). "Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs". Cold Spring Harb. Symp. Quant. Biol. 71: 59–66.
- Park, JE; Heo, I; Tian, Y; Simanshu, DK; Chang, H; Jee, D; Patel, DJ; Kim, VN (13 July 2011). "Dicer recognizes the 5' end of RNA for efficient and accurate processing.". Nature 475 (7355): 201–5.
- Ji X (2008). "The mechanism of RNase III action: how dicer dices". Curr. Top. Microbiol. Immunol. Current Topics in Microbiology and Immunology 320: 99–116.
- Mirihana Arachchilage G, Dassanayake AC, Basu S (2015). "A Potassium Ion-Dependent RNA Structural Switch Regulates Human Pre-miRNA 92b Maturation". Chemistry & Biology 22: 262–272.
- Lelandais-Brière C, Sorin C, Declerck M, Benslimane A, Crespi M, Hartmann C; Sorin; Declerck; Benslimane; Crespi; Hartmann (March 2010). "Small RNA diversity in plants and its impact in development".
- Rana TM (January 2007). "Illuminating the silence: understanding the structure and function of small RNAs". Nat. Rev. Mol. Cell Biol. 8 (1): 23–36.
- Schwarz DS, Zamore PD; Zamore (May 2002). "Why do miRNAs live in the miRNP?". Genes Dev. 16 (9): 1025–31.
- Krol J, Sobczak K, Wilczynska U, Drath M, Jasinska A, Kaczynska D, Krzyzosiak WJ; Sobczak; Wilczynska; Drath; Jasinska; Kaczynska; Krzyzosiak (2004). "Structural features of microRNA (miRNA) precursors and their relevance to miRNA biogenesis and small interfering RNA/short hairpin RNA design". J Biol Chem 279 (40): 42230–9.
- Khvorova A, Reynolds A, Jayasena SD; Reynolds; Jayasena (2003). "Functional siRNAs and miRNAs exhibit strand bias". Cell 115 (2): 209–16.
- Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD; Hutvágner; Du; Xu; Aronin; Zamore (2003). "Asymmetry in the assembly of the RNAi enzyme complex". Cell 115 (2): 199–208.
- Lin SL, Chang D, Ying SY; Chang; Ying (2005). "Asymmetry of intronic pre-miRNA structures in functional RISC assembly". Gene 356: 32–8.
- Okamura K, Chung WJ, Lai EC; Chung; Lai (2008). "The long and short of inverted repeat genes in animals: microRNAs, mirtrons and hairpin RNAs". Cell Cycle 7 (18): 2840–5.
- Pratt AJ, MacRae IJ; MacRae (July 2009). "The RNA-induced silencing complex: a versatile gene-silencing machine". J. Biol. Chem. 284 (27): 17897–901.
- MacRae IJ, Ma E, Zhou M, Robinson CV, Doudna JA; Ma; Zhou; Robinson; Doudna (January 2008). "In vitro reconstitution of the human RISC-loading complex". Proc. Natl. Acad. Sci. U.S.A. 105 (2): 512–7.
- Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss G; Dostie; Paushkin; Sharma; Charroux; Abel; Rappsilber; Mann; Dreyfuss (March 2002). "miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs". Genes Dev. 16 (6): 720–8.
- Meister G, Landthaler M, Peters L, Chen P, Urlaub H, Lurhmann R, Tuschl T; Landthaler; Peters; Chen; Urlaub; Lührmann; Tuschl (December 2005). "Identification of Novel Argonaute-Associated Proteins". Current Biology 15 (23): 2149–55.
- Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J (2005). "Involvement of microRNA in AU-rich element-mediated mRNA instability". Cell 120 (5): 623–34.
- Musilova K, Mraz M; Mraz (2014). "MicroRNAs in B cell lymphomas: How a complex biology gets more complex". Leukemia.
- Kai ZS, Pasquinelli AE; Pasquinelli (January 2010). "MicroRNA assassins: factors that regulate the disappearance of miRNAs". Nat. Struct. Mol. Biol. 17 (1): 5–10.
- Chatterjee S, Großhans H; Grosshans (September 2009). "Active turnover modulates mature microRNA activity in Caenorhabditis elegans". Nature 461 (7263): 546–459.
- Morozova N, Zinovyev A, Nonne N, Pritchard LL, Gorban AN, Harel-Bellan A (September 2012). "Kinetic signatures of microRNA modes of action". RNA 18 (9): 1635–55.
- Wang XJ, Reyes JL, Chua NH, Gaasterland T; Reyes; Chua; Gaasterland (2004). "Prediction and identification of Arabidopsis thaliana microRNAs and their mRNA targets". Genome Biol. 5 (9): R65.
- Kawasaki H, Taira K; Taira (2004). "MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells". Nucleic Acids Symp Ser 48 (1): 211–2.
- Moxon S, Jing R, Szittya G, Schwach F, Rusholme Pilcher RL, Moulton V, Dalmay T; Jing; Szittya; Schwach; Rusholme Pilcher; Moulton; Dalmay (October 2008). "Deep sequencing of tomato short RNAs identifies microRNAs targeting genes involved in fruit ripening". Genome Res. 18 (10): 1602–9.
- Mazière P, Enright AJ; Enright (June 2007). "Prediction of microRNA targets". Drug Discov. Today 12 (11–12): 452–8.
- Williams AE (February 2008). "Functional aspects of animal microRNAs". Cell. Mol. Life Sci. 65 (4): 545–62.
- Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E; Huntzinger; Nishihara; Rehwinkel; Fauser; Izaurralde (January 2009). "Deadenylation is a widespread effect of miRNA regulation". RNA 15 (1): 21–32.
- Bazzini AA, Lee MT, Giraldez AJ; Lee; Giraldez (April 2012). "Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish". Science 336 (6078): 233–7.
- Djuranovic S, Nahvi A, Green R; Nahvi; Green (April 2012). "miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay". Science 336 (6078): 237–40.
- Tan Y, Zhang B, Wu T, Skogerbø G, Zhu X, Guo X, He S, Chen R; Zhang; Wu; Skogerbø; Zhu; Guo; He; Chen (2009). "Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells". BMC Mol. Biol. 10 (1): 12.
- Hawkins PG, Morris KV; Morris (March 2008). "RNA and transcriptional modulation of gene expression". Cell Cycle 7 (5): 602–7.
- Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM; Brennecke; Bushati; Russell; Cohen (2005). "Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution". Cell 123 (6): 1133–46.
- Li LC (2008). "Small RNA-Mediated Gene Activation". RNA and the Regulation of Gene Expression: A Hidden Layer of Complexity. Caister Academic Press.
- Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R (2008). "MicroRNA-373 induces expression of genes with complementary promoter sequences". Proc. Natl. Acad. Sci. U.S.A. 105 (5): 1608–13.
- Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (August 2011). "A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?". Cell 146 (3): 353–8.
- Wheeler BM, Heimberg AM, Moy VN, Sperling EA, Holstein TW, Heber S, Peterson KJ (2009). "The deep evolution of metazoan microRNAs". Evol. Dev. 11 (1): 50–68.
- Pashkovskiy, P. P.; Ryazansky, S. S. (2013). "Biogenesis, evolution, and functions of plant microRNAs". Biochemistry-Moscow 78 (6): 627–637.
- Heimberg AM, Sempere LF, Moy VN, Donoghue PC, Peterson KJ (February 2008). "MicroRNAs and the advent of vertebrate morphological complexity". Proc. Natl. Acad. Sci. U.S.A. 105 (8): 2946–50.
- Peterson KJ, Dietrich MR, McPeek MA (July 2009). "MicroRNAs and metazoan macroevolution: insights into canalization, complexity, and the Cambrian explosion". BioEssays 31 (7): 736–47.
- Nozawa M, Miura S, Nei M (2010). "Origins and evolution of microRNA genes in Drosophila species". Genome Biol Evol 2: 180–9.
- Allen, E.; Z. X. Xie; A. M. Gustafson; G. H. Sung; J. W. Spatafora; J. C. Carrington (2004). "Evolution of microRNA genes by inverted duplication of target gene sequences in Arabidopsis thaliana". Nature Genetics 36 (12): 1282–1290.
- Warthmann, N.; S. Das; C. Lanz; D. Weigel (2008). "Comparative analysis of the MIR319a MicroRNA locus in Arabidopsis and related Brassicaceae". Molecular Biology and Evolution 25 (5): 892–902.
- Fahlgren, N.; S. Jogdeo; K. D. Kasschau; C. M. Sullivan; E. J. Chapman; S. Laubinger; L. M. Smith; M. Dasenko; S. A. Givan; D. Weigel; J. C. Carrington (2010). "MicroRNA gene evolution in Arabidopsis lyrata and Arabidopsis thaliana". Plant Cell 22 (4): 1074–1089.
- Caravas J, Friedrich M (June 2010). "Of mites and millipedes: recent progress in resolving the base of the arthropod tree". BioEssays 32 (6): 488–95.
- Cock JM, Sterck L, Rouzé P, Scornet D, Allen AE, Amoutzias G, Anthouard V, Artiguenave F, Aury JM, Badger JH; et al. (June 2010). "The Ectocarpus genome and the independent evolution of multicellularity in brown algae". Nature 465 (7298): 617–21.
- Cuperus, J. T.; N. Fahlgren,; J. C. Carrington (2011). "Evolution and functional diversification of MIRNA genes". Plant Cell 23 (2): 431–442.
- Ryan, J. F.; Pang, K.; Schnitzler, C. E.; Nguyen, A.-D.; Moreland, R. T.; Simmons, D. K.; Koch, B. J.; Francis, W. R.; Havlak, P.; Smith, S. A.; Putnam, N. H.; Haddock, S. H. D.; Dunn, C. W.; Wolfsberg, T. G.; Mullikin, J. C.; Martindale, M. Q.; Baxevanis, A. D. (2013). "The Genome of the Ctenophore Mnemiopsis leidyi and Its Implications for Cell Type Evolution". Science 342 (6164): 1242592.
- Maxwell, E.K.; Ryan, J.F.; Schnitzler, C.E.; Browne, W.E.; Baxevanis, A.D. (December 2012). "Mnemiopsis leidyi"MicroRNAs and essential components of the microRNA processing machinery are not encoded in the genome of the ctenophore . BMC Genomics 13 (1): 714.
- Dimond PF (15 March 2010). "miRNAs' Therapeutic Potential". Genetic Engineering & Biotechnology News 30 (6). p. 1. Archived from the original on 10 July 2010. Retrieved 10 July 2010.
- Tjaden B, Goodwin SS, Opdyke JA, Guillier M, Fu DX, Gottesman S, Storz G (2006). "Target prediction for small, noncoding RNAs in bacteria". Nucleic Acids Res. 34 (9): 2791–802.
- Mraz M, Malinova K, Mayer J, Pospisilova S (December 2009). "MicroRNA isolation and stability in stored RNA samples". Biochem. Biophys. Res. Commun. 390 (1): 1–4.
- Liu CG, Calin GA, Volinia S, Croce CM (2008). "MicroRNA expression profiling using microarrays". Nat Protoc 3 (4): 563–78.
- Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ (2005). "Real-time quantification of microRNAs by stem-loop RT-PCR". Nucleic Acids Res. 33 (20): e179.
- Shingara J, Keiger K, Shelton J, Laosinchai-Wolf W, Powers P, Conrad R, Brown D, Labourier E (September 2005). "An optimized isolation and labeling platform for accurate microRNA expression profiling". RNA 11 (9): 1461–70.
- Buermans HP, Ariyurek Y, van Ommen G, den Dunnen JT, 't Hoen PA. (December 2010). "New methods for next generation sequencing based microRNA expression profiling". BMC Genomics 11: 716.
- Kloosterman WP, Wienholds E, Ketting RF, Plasterk RH (2004). "Substrate requirements for let-7 function in the developing zebrafish embryo". Nucleic Acids Res. 32 (21): 6284–91.
- Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG (February 2007). "Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate". Nat. Genet. 39 (2): 259–63.
- Meister G, Landthaler M, Dorsett Y, Tuschl T (March 2004). "Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing". RNA 10 (3): 544–50.
- Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH (August 2007). "Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development". PLoS Biol. 5 (8): e203.
- Choi WY, Giraldez AJ, Schier AF (October 2007). "Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430". Science 318 (5848): 271–4.
- You Y, Moreira BG, Behlke MA, Owczarzy R (2006). "Design of LNA probes that improve mismatch discrimination". Nucleic Acids Res 34 (8): e60.
- Lagendijk AK, Moulton JD, Bakkers J (2012). "Revealing details: whole mount microRNA in situ hybridization protocol for zebrafish embryos and adult tissues". Bio Open 1 (6): 566–569.
- Kaur H, Arora A, Wengel J, Maiti S, Arora A, Wengel J, Maiti S (2006). "Thermodynamic, Counterion, and Hydration Effects for the Incorporation of Locked Nucleic Acid Nucleotides into DNA Duplexes". Biochemistry 45 (23): 7347–55.
- Nielsen JA, Lau P, Maric D, Barker JL, Hudson LD (2009). "Integrating microRNA and mRNA expression profiles of neuronal progenitors to identify regulatory networks underlying the onset of cortical neurogenesis". BMC Neurosci 10: 98.
- Gupta A, Nagilla P, Le HS, Bunney C, Zych C, Thalamuthu A, Bar-Joseph Z, Mathavan S, Ayyavoo V (2011). Mammano, Fabrizio, ed. "Comparative expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells infected with human immunodeficiency virus (HIV-1)". PLoS ONE 6 (7): e22730.
- Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP (July 2007). "MicroRNA targeting specificity in mammals: determinants beyond seed pairing". Mol. Cell 27 (1): 91–105.
- Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (January 2008). "miRBase: tools for microRNA genomics". Nucleic Acids Res. 36 (Database issue): D154–8.
- Nam S, Li M, Choi K, Balch C, Kim S, Nephew KP (July 2009). "MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression". Nucleic Acids Res. 37 (Web Server issue): W356–62.
- Artmann S, Jung K, Bleckmann A, Beissbarth T (2012). Provero, Paolo, ed. "Detection of simultaneous group effects in microRNA expression and related target gene sets". PLoS ONE 7 (6): e38365.
- Mraz M, Pospisilova S (December 2012). "MicroRNAs in chronic lymphocytic leukemia: from causality to associations and back". Expert Review of Hematology 5 (6): 579–81.
- Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y. (January 2009). "miR2Disease: a manually curated database for microRNA deregulation in human disease". Nucleic Acids Research. 37. (Database issue) (Database issue): D98–104.
- Mencía A, Modamio-Høybjør S, Redshaw N, Morín M, Mayo-Merino F, Olavarrieta L, Aguirre LA, del Castillo I, Steel KP, Dalmay T, Moreno F, Moreno-Pelayo MA (May 2009). "Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss". Nat. Genet. 41 (5): 609–13.
- Hughes AE, Bradley DT, Campbell M, Lechner J, Dash DP, Simpson DA, Willoughby CE (2011). "Mutation Altering the miR-184 Seed Region Causes Familial Keratoconus with Cataract". The American Journal of Human Genetics 89 (5): 628–633.
- de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S, Van Haeringen A, Geneviève D, Goldenberg A, Oufadem M, Manouvrier S, Munnich A, Vidigal JA, Vekemans M, Lyonnet S, Henrion-Caude A, Ventura A, Amiel J (October 2011). "Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans". Nat. Genet. 43 (10): 1026–30.
- Kusenda B, Mraz M, Mayer J, Pospisilova S (November 2006). "MicroRNA biogenesis, functionality and cancer relevance" (PDF). Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia 150 (2): 205–15.
- Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J (March 2009). "MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes". Leuk. Lymphoma 50 (3): 506–9.
- He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM (June 2005). "A microRNA polycistron as a potential human oncogene". Nature 435 (7043): 828–33.
- Cui JW, Li YJ, Sarkar A, Brown J, Tan YH, Premyslova M, Michaud C, Iscove N, Wang GJ, Ben-David Y. (June 2007). "Retroviral insertional activation of the Fli-3 locus in erythroleukemias encoding a cluster of microRNAs that convert Epo-induced differentiation to proliferation". Blood 110 (7): 2631–40.
- O'Donnell KA, Wentzel EA, Zeller KI, Dang CV,
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (June 2005). "MicroRNA expression profiles classify human cancers". Nature 435 (7043): 834–8.
- Zanesi N, Pekarsky Y, Trapasso F, Calin G, Croce CM (2010). "MicroRNAs in mouse models of lymphoid malignancies". J Nucleic Acids Investig 1 (1): 36–40.
- Jun Qian, Vinayakumar Siragam, Jiang Lin, Jichun Ma, Zhaoqun Deng (2011). "The role of microRNAs in the formation of cancer stem cells: Future directions for miRNAs". Hypothesis 9 (1): e10.
- "Screening Tool Can Detect Colorectal Cancer from a Small Blood Sample" (Press release). American Association for Cancer Research. 29 September 2010. Retrieved 29 November 2010.
- Nielsen BS, Jørgensen S, Fog JU, Søkilde R, Christensen IJ, Hansen U, Brünner N, Baker A, Møller S, Nielsen HJ (October 2010). "High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients". Clin Exp Metastasis 28 (1): 27–38.
- Võsa U, Vooder T, Kolde R, Fischer K, Välk K, Tõnisson N, Roosipuu R, Vilo J, Metspalu A, Annilo T (October 2011). "Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer". Genes Chromosomes Cancer 50 (10): 812–22.
- Akçakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata DM, Xie H, Lindforss U, Olivecrona H, Lui WO (August 2011). "miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer". Int. J. Oncol. 39 (2): 311–8.
- MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. Guangxian Xu et al, 2013
- Jones, K; Nourse JP; Keane C; Bhatnagar A; Gandhi MK. (Jan 2014). "Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma". Clin Can Res 20 (1): 253–64.
- Wu H, Mo YY (December 2009). "Targeting miR-205 in breast cancer". Expert Opin. Ther. Targets 13 (12): 1439–48.
- Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (May 2008). "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1". Nat. Cell Biol. 10 (5): 593–601.
- Bernstein C, Prasad AR Nfonsam V, Bernstei H (2013). "DNA Damage, DNA Repair and Cancer". New Research Directions in DNA Repair. pp. 413–65.
- O'Hagan, HM; Mohammad, HP; Baylin, SB (2008). "Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island". PLoS Genet 4 (8): e1000155.
- Cuozzo, C; Porcellini, A; Angrisano, T; Morano, A; Lee, B; Di Pardo, A; Messina, S; Iuliano, R; Fusco, A; Santillo, MR; Muller, MT; Chiariotti, L; Gottesman, ME; Avvedimento, EV (2007). "DNA damage, homology-directed repair, and DNA methylation". PLoS Genet 3 (7): e110.
- Jasperson, KW; Tuohy, TM; Neklason, DW; Burt, RW (2010). "Hereditary and familial colon cancer". Gastroenterology 138 (6): 2044–2058.
- Truninger K, Menigatti M, Luz J, et al. (May 2005). "Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer". Gastroenterology 128 (5): 1160–71.
- Valeri N, Gasparini P, Fabbri M, et al. (April 2010). "Modulation of mismatch repair and genomic stability by miR-155". Proc. Natl. Acad. Sci. U.S.A. 107 (15): 6982–7.
- Zhang W, Zhang J, Hoadley K, et al. (June 2012). "miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression". Neuro-oncology 14 (6): 712–9.
- Spiegl-Kreinecker S, Pirker C, Filipits M, et al. (January 2010). "O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients". Neuro-oncology 12 (1): 28–36.
- Sgarra R, Rustighi A, Tessari MA, et al. (September 2004). "Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer". FEBS Lett. 574 (1–3): 1–8.
- Xu Y, Sumter TF, Bhattacharya R, et al. (May 2004). "The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia". Cancer Res. 64 (10): 3371–5.
- Baldassarre G, Battista S, Belletti B, et al. (April 2003). "Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma". Mol. Cell. Biol. 23 (7): 2225–38.
- Borrmann L, Schwanbeck R, Heyduk T, et al. (December 2003). "High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity". Nucleic Acids Res. 31 (23): 6841–51.
- Facista A, Nguyen H, Lewis C, Prasad AR, Ramsey L, Zaitlin B, Nfonsam V, Krouse RS, Bernstein H, Payne CM, Stern S, Oatman N, Banerjee B, Bernstein C (2012). "Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer". Genome Integrity 3 (1): 3.
- Palmieri D, D'Angelo D, Valentino T, et al. (August 2012). "Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis". Oncogene 31 (34): 3857–65.
- Malumbres M (2013). "miRNAs and cancer: an epigenetics view". Mol. Aspects Med. 34 (4): 863–74.
- Schnekenburger M, Diederich M (March 2012). "Epigenetics Offer New Horizons for Colorectal Cancer Prevention". Curr Colorectal Cancer Rep 8 (1): 66–81.
- Sampath D, Liu C, Vasan K, et al. (February 2012). "Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia". Blood 119 (5): 1162–72.
- Son DJ, Kumar S, Takabe W, Kim CW, Ni CW, Alberts-Grill N, Jang IH, Kim S, Kim W, Won Kang S, Baker AH, Woong Seo J, Ferrara KW, Jo H (2013). "The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis". Nature Communications 4: 3000.
- Wan G, Mathur R, Hu X, Zhang X, Lu X (September 2011). "miRNA response to DNA damage". Trends Biochem. Sci. 36 (9): 478–84.
- Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Vecchiotti D, Capece D, Zazzeroni F, Alesse E (2014). "MicroRNAs in the DNA Damage/Repair Network and Cancer". Int J Genomics 2014: 820248.
- Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ (February 2008). "Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure". Proc. Natl. Acad. Sci. U.S.A. 105 (6): 2111–6.
- Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D (April 2007). "Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2". Cell 129 (2): 303–17.
- Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G,
- van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN (November 2006). "A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure". Proc. Natl. Acad. Sci. U.S.A. 103 (48): 18255–60.
- Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ (June 2007). "Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy". J. Mol. Cell. Cardiol. 42 (6): 1137–41.
- Zhao Y, Samal E, Srivastava D (July 2005). "Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis". Nature 436 (7048): 214–20.
- Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, Zhang Y, Yang B, Wang Z (April 2007). "MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts". J. Biol. Chem. 282 (17): 12363–7.
- Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z (April 2007). "The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2". Nat. Med. 13 (4): 486–91.
- Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G (May 2007). "MicroRNA-133 controls cardiac hypertrophy". Nat. Med. 13 (5): 613–8.
- van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN (April 2007). "Control of stress-dependent cardiac growth and gene expression by a microRNA". Science 316 (5824): 575–9.
- Wagschal, Alexandre (2 September 2015). "Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis".
- Insull W (January 2009). "The pathology of atherosclerosis: plaque development and plaque responses to medical treatment". The American Journal of Medicine 122 (1 Suppl): S3–S14.
- Basu R, Fan D, Kandalam V, Lee J, Das SK, Wang X, Baldwin TA, Oudit GY, Kassiri Z (December 2012). "Loss of Timp3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II". The Journal of Biological Chemistry 287 (53): 44083–96.
- Libby P (2002). "Inflammation in atherosclerosis". Nature 420 (6917): 868–74.
- Phua, YL; Chu, JY; Marrone, AK; Bodnar, AJ; Sims-Lucas, S; Ho, J (October 2015). "Renal stromal miRNAs are required for normal nephrogenesis and glomerular mesangial survival.". Physiological reports 3 (10).
- Maes OC, Chertkow HM, Wang E, Schipper HM (May 2009). "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders". Current Genomics 10 (3): 154–68.
- Schratt G (December 2009). "microRNAs at the synapse". Nat. Rev. Neurosci. 10 (12): 842–9.
- Hommers LG, Domschke K, Deckert J (2015). "Heterogeneity and Individuality: microRNAs in Mental Disorders". J Neural Transm. 122 (1): 79–97.
- Feng J, Sun G, Yan J, Noltner K, Li W, Buzin CH, Longmate J, Heston LL, Rossi J, Sommer SS (2009). Reif, Andreas, ed. "Evidence for X-chromosomal schizophrenia associated with microRNA alterations". PLoS ONE 4 (7): e6121.
- Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ (September 2009). "Schizophrenia is associated with an increase in cortical microRNA biogenesis". Mol. Psychiatry 15 (12): 1176–89.
- Lewohl JM, Nunez YO, Dodd PR, Tiwari GR, Harris RA, Mayfield RD (2011). "Up-regulation of microRNAs in brain of human alcoholics". Alcohol Clin Exp Res. 35 (11): 1928–37.
- Tapocik JD, Solomon M, Flanigan M, Meinhardt M, Barbier E, Schank JR, Schwandt M, Sommer WH, Heilig M (2013). "Coordinated dysregulation of mRNAs and microRNAs in the rat medial prefrontal cortex following a history of alcohol dependence". Pharmacogenomics J 13 (3): 286–96.
- Gorini G, Nunez YO, Mayfield RD (2013). "Integration of miRNA and protein profiling reveals coordinated neuroadaptations in the alcohol-dependent mouse brain". PLOS ONE 8 (12): e82565.
- Tapocik JD, Barbier E, Flanigan M, Solomon M, Pincus A, Pilling A, Sun H, Schank JR, King C, Heilig M (2014). "microRNA-206 in rat medial prefrontal cortex regulates BDNF expression and alcohol drinking". J Neurosci. 34 (13): 4581–4588.
- Lippai D, Bala S, Csak T, Kurt-Jones EA, Szabo G (2013). "Chronic alcohol-induced microRNA-155 contributes to neuroinflammation in a TLR4-dependent manner in mice". PLOS ONE 8 (8): e70945.
- Li J, Li J, Liu X, Qin S, Guan Y, Liu Y, Cheng Y, Chen X, Li W, Wang S, Xiong M, Kuzhikandathil EV, Ye JH, Zhang C (2013). "MicroRNA expression profile and functional analysis reveal that miR-382 is a critical novel gene of alcohol addiction". EMBO Mol Med. 5 (9): 1402–14.
- Romao JM, Jin W, Dodson MV, Hausman GJ, Moore SS, Guan LL (September 2011). "MicroRNA regulation in mammalian adipogenesis". Exp. Biol. Med. (Maywood) 236 (9): 997–1004.
- Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O (April 2012). "Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222". Stem Cells Dev. 21 (6): 873–83.
- Zuo Y, Qiang L, Farmer SR (March 2006). "Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/ebp alpha gene promoter". J. Biol. Chem. 281 (12): 7960–7.
- Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, Urbach A, Thornton JE, Triboulet R, Gregory RI; DIAGRAM Consortium; MAGIC Investigators, Altshuler D, Daley GQ (September 2011). "The Lin28/let-7 axis regulates glucose metabolism". Cell 147 (1): 81–94.
- Frost RJ, Olson EN. (December 2011). "Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs". Proc Natl Acad Sci U S A. 108 (52): 21075–80.
- Pheasant M, Mattick JS (September 2007). "Raising the estimate of functional human sequences". Genome Res. 17 (9): 1245–53.
- Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, Rinn JL, Tongprasit W, Samanta M, Weissman S, Gerstein M, Snyder M (December 2004). "Global identification of human transcribed sequences with genome tiling arrays". Science 306 (5705): 2242–6.
- Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M; et al. (January 2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5.
- Kuhn DE, Martin MM, Feldman DS, Terry AV, Nuovo GJ, Elton TS (January 2008). "Experimental validation of miRNA targets". Methods 44 (1): 47–54.
- Hüttenhofer A, Schattner P, Polacek N (May 2005). "Non-coding RNAs: hope or hype?". Trends Genet. 21 (5): 289–97.
- Tuddenham L, Jung JS, Chane-Woon-Ming B, Dölken L, Pfeffer S (February 2012). "Small RNA deep sequencing identifies microRNAs and other small noncoding RNAs from human herpesvirus 6B". J. Virol. 86 (3): 1638–49.
- Zheng H, Fu R, Wang JT, Liu Q, Chen H, Jiang SW (Apr 2013). "Advances in the Techniques for the Prediction of microRNA Targets". Int J Mol Sci. 14 (4): 8179–87.
- Agarwal, Vikram; Bell, George W.; Nam, Jin-Wu; Bartel, David P. (2015-08-12). "Predicting effective microRNA target sites in mammalian mRNAs". eLife 4: e05005.
- Gene expression
- List of miRNA gene prediction tools
- List of miRNA target prediction tools
- Small nucleolar RNA derived microRNA
- Anti-miRNA oligonucleotides
- See also: List of miRNA target prediction tools
miRNAs can bind to target messenger RNA (mRNA) transcripts of protein-coding genes and negatively control their translation or cause mRNA degradation. It is of key importance to identify the miRNA targets accurately. A detailed review for the advances in the miRNA target identification methods and available resources has been published by Zheng et al. A comparison of the predictive performance of eighteen in silico algorithms is available in Agarwal et al.
The expression of transcription activators by human herpesvirus-6 DNA, is believed to be regulated by viral miRNA.
When the human genome project mapped its first chromosome in 1999, it was predicted the genome would contain over 100,000 protein coding genes. However, only around 20,000 were eventually identified (International Human Genome Sequencing Consortium, 2004). Since then, the advent of bioinformatics approaches combined with genome tiling studies examining the transcriptome, systematic sequencing of full length cDNA libraries, and experimental validation (including the creation of miRNA derived antisense oligonucleotides called antagomirs) have revealed that many transcripts are non protein-coding RNA, including several snoRNAs and miRNAs.
Another class of miRNAs that regulate insulin resistance, obesity, and diabetes, is the let-7 family. Let-7 is known to accumulate in human tissues during the course of aging. When let-7 was ectopically overexpressed to mimic accelerated aging, mice became insulin-resistant, and thus more prone to high fat diet-induced obesity and diabetes. In contrast when let-7 was inhibited by injections of let-7-specific antagomirs, mice become more insulin-sensitive, and remarkably resistant to high fat diet-induced obesity and diabetes. Not only could let-7 inhibition prevent obesity and diabetes, it could also reverse and cure diabetes. These experimental findings suggest that let-7 inhibition could represent a new therapy for obesity and type 2 diabetes.
miRNAs play crucial roles in the regulation of stem cell progenitors differentiating into adipocytes. Studies to determine what role pluripotent stem cells play in adipogenesis, were examined in the immortalized human bone marrow-derived stromal cell line hMSC-Tert20. Decreased expression of miR-155,miR-221,and miR-222, have been found during the adipogenic programming of both immortalized and primary hMSCs, suggesting that they act as negative regulators of differentiation. Conversely, ectopic expression of the miRNAs 155,221, and 222 significantly inhibited adipogenesis and repressed induction of the master regulators PPARγ and CCAAT/enhancer-binding protein alpha (CEBPA). This paves the way for possible obesity treatments on the genetic level.
miRNAs can be either upregulated or downregulated in response to chronic alcohol use. miR-206 expression increased in the prefrontal cortex of alcohol dependent rats, targeting the transcription factor Brain-derived neurotrophic factor, or BDNF and ultimately reducing its expression. BDNF plays a critical role in the formation and maturation of new neurons and synapses, suggesting a possible implication in synapse growth/synaptic plasticity in alcohol abusers. miR-155, important in regulating alcohol-induced neuroinflammation responses, was also found to be upregulated, suggesting the role of microglia and inflammatory cytokines in alcohol pathophysiology. Downregulation of miR-382 was found in the nucleus accumbens, a structure in the basal forebrain significant in regulating feelings of reward that power motivational habits. miR-382 is the target for the dopamine receptor D1 (DRD1), and its overexpression results in the upregulation of DRD1 and delta fosB, a transcription factor which activates a series of transcription events in the nucleus accumbens that ultimately result in addictive behaviors. Alternatively, overexpressing miR-382 resulted in attenuated drinking and the inhibition of DRD1 and delta fosB upregulation in rat models of alcoholism, demonstrating the possibility of using miRNA-targeted pharmaceuticals in the treatment of alcoholism.
The vital role of miRNAs in gene expression is significant to withdrawal and/or dependence. Up to 35 different miRNAs have been found to be altered in the alcoholic post-mortem brain, all of which target genes that include the regulation of the cell cycle, apoptosis, cell adhesion, nervous system development, and cell signaling. Altered miRNA levels were also found in the medial prefrontal cortex of alcohol-dependent mice, suggesting the role of miRNA in orchestrating translational imbalances and the creation of differentially expressed proteins within an area of the brain where complex cognitive behavior and decision making likely originate.
miRNAs appear to regulate the development and function of the nervous system. Neural miRNAs are involved at various stages of synaptic development, including dendritogenesis (involving miR-132, miR-134 and miR-124), synapse formation and synapse maturation (where miR-134 and miR-138 are thought to be involved). Some studies find altered miRNA expression in schizophrenia, as well as bipolar disorder, and major depression and anxiety disorders.
Targeted deletion of Dicer in the FoxD1-derived renal progenitor cells in a murine model resulted in a complex renal phenotype including expansion of nephron progenitors, fewer renin cells, smooth muscle arterioles, progressive mesangial loss and glomerular aneurysms. High throughput whole transcriptome profiling of the FoxD1-Dicer knockout mouse model revealed ectopic upregulation of pro-apoptotic gene, Bcl2L11 (Bim) and dysregulation of the p53 pathway with increase in p53 effector genes including Bax, Trp53inp1, Jun, Cdkn1a, Mmp2, and Arid3a. Interestingly, p53 protein levels remained unchanged, suggesting that FoxD1 stromal miRNAs directly repress p53-effector genes. Using a lineage tracing approach followed by Fluorescent Activated Cell Sorting, miRNA profiling of the FoxD1-derived cells not only comprehensively defined the transcriptional landscape of miRNAs that are critical for vascular development, but also identified key miRNAs that are likely to modulate the renal phenotype in its absence. These miRNAs include miRs‐10a, 18a, 19b, 24, 30c, 92a, 106a, 130a, 152, 181a, 214, 222, 302a, 370, and 381 that regulate Bcl2L11 (Bim) and miRs‐15b, 18a, 21, 30c, 92a, 106a, 125b‐5p, 145, 214, 222, 296‐5p and 302a that regulate p53-effector genes. Consistent with the profiling results, ectopic apoptosis was observed in the cellular derivatives of the FoxD1 derived progenitor lineage and reiterates the importance of renal stromal miRNAs in cellular homeostasis.
When tested, d-flow decreased the expression of XRN1 in humans as it did in mice endothelial cells, indicating that there may be a common role of XRN1 in human. While the human homolog has not been thoroughly studied, the discovery and function of miRNA-712 can give weight for future research on its potential as a biomarker in mice models of atherosclerosis.
The human homolog of miR-712 was found on the RN45s homolog gene, which maintains similar miRNAs to mice. MiR-205 of humans share similar sequences with miR-712 of mice and is conserved across most vertebrates. MiR-205 and miR-712 also share more than 50% of the cell signaling targets, including TIMP3.
Human Homolog microRNA-205
Anti-miR-712 effectively suppresses d-flow induced miR-712 expression and increases TIMP3 expression. Anti-miR-712 also inhibits vascular hyperpermeability, thereby significantly reducing atherosclerosis lesion development and immune cell infiltration.
TIMP3 also decreases the expression of TNFα (a pro-inflammatory regulator) during turbulent flow. Activity of TNFα in turbulent flow was measured by the expression of TNFα converting enzyme (TACE) in blood. TNFα decreased if miR-712 was inhibited or TIMP3 overexpressed, suggesting that miR-712 and TIMP3 regulate TACE activity in turbulent flow conditions.
MiR-712 targets tissue inhibitor of metalloproteinases 3 (TIMP3). TIMPs normally regulate activity of matrix metalloproteinases (MMPs) which degrade the extracellular matrix (ECM). Arterial ECM is mainly composed of collagen and elastin fibers, providing the structural support and recoil properties of arteries. These fibers play a critical role in regulation of vascular inflammation and permeability, which are important in the development of atherosclerosis. Expressed by endothelial cells, TIMP3 is the only ECM bound TIMP. A decrease in TIMP3 expression results in an increase of ECM degradation in the presence of d-flow. Consistent with these findings, inhibition of pre-miR712 increases expression of TIMP3 in cells, even when exposed to turbulent flow.
Pre-mRNA sequence of miR-712 is generated from the murine ribosomal RN45s gene at the internal transcribed spacer region 2 (ITS2). XRN1 is an exonuclease that degrades the ITS2 region during processing of RN45s. Reduction of XRN1 under d-flow conditions therefore leads to the accumulation of miR-712.
Murine microRNA-712 is a potential biomarker (i.e. predictor) for atherosclerosis, a cardiovascular disease of the arterial wall associated with lipid retention and inflammation. Non-laminar blood flow also correlates with development of atherosclerosis as mechanosenors of epithelial cells respond to the sheer force of disturbed flow (d-flow). A number of pro-atherogenic genes including matrix metalloproteinases (MMPs) are upregulated by d-flow , mediating pro-inflammatory and pro-angiogenic signals. These findings were observed in ligated carotid arteries of mice to mimic the effects of d-flow. Within 24 hours, pre-existing immature miR-712 formed mature miR-712 suggesting that miR-712 is flow-sensitive. Coinciding with these results, miR-712 is also upregulated in endothelial cells exposed to naturally occurring d-flow in the greater curvature of the aortic arch.
The global role of miRNA function in the heart has been addressed by conditionally inhibiting miRNA maturation in the murine heart, and has revealed that miRNAs play an essential role during its development. miRNA expression profiling studies demonstrate that expression levels of specific miRNAs change in diseased human hearts, pointing to their involvement in cardiomyopathies. Furthermore, studies on specific miRNAs in animal models have identified distinct roles for miRNAs both during heart development and under pathological conditions, including the regulation of key factors important for cardiogenesis, the hypertrophic growth response, and cardiac conductance. miRNA's in animal models have also been linked to cholesterol metabolism and regulation.
In contrast to the previous example, where under-expression of miRNAs indirectly caused reduced expression of DNA repair genes, in some cases over-expression of certain miRNAs may directly reduce expression of specific DNA repair proteins. Wan et al. referred to 6 DNA repair genes that are directly targeted by the miRNAs indicated: ATM (miR-421), RAD52 (miR-210, miR-373), RAD23B (miR-373), MSH2 (miR-21), BRCA1 (miR-182) and P53 (miR-504, miR-125b). More recently, Tessitore et al. listed multiple DNA repair genes directly targeted by these additional miRNAs: ATM (miR-100, miR18a, miR-101), DNA-PK (miR-101), ATR (mir-185), Wip1 (miR-16), MLH1, MSH2, MSH6 (miR-155), ERCC3, ERCC4 (miR-192) and UNG2 (miR-16, miR-34c). Among these miRNAs, miR-16, miR-18a, miR-21, miR-34c, miR-101, miR-125b, miR-155, miR-182, miR-185, miR-192 and miR-373 were identified by Schnekenburger and Diederich as over-expressed in colon cancer through epigenetic hypomethylation. Over expression of any one of these miRNAs can cause reduced expression of its target DNA repair gene.
HMGA2 protein specifically targets the promoter of ERCC1, thus reducing expression of this DNA repair gene. ERCC1 protein expression was deficient in 100% of 47 evaluated colon cancers (though the extent to which HGMA2 was involved is not known). Palmieri et al. showed that, in normal tissues, HGMA1 and HMGA2 genes are targeted (and thus strongly reduced in expression) by miR-15, miR-16, miR-26a, miR-196a2 and Let-7a. However, each of these HMGA-targeting miRNAs are drastically reduced in almost all human pituitary adenomas studied, when compared with the normal pituitary gland. Consistent with the down-regulation of these HMGA-targeting miRNAs, an increase in the HMGA1 and HMGA2-specific mRNAs was observed. Three of these microRNAs (miR-16, miR-196a and Let-7a) have methylated promoters and therefore low expression in colon cancer. For two of these, miR-15 and miR-16, the coding regions are epigenetically silenced in cancer due to histone deacetylase activity. When these microRNAs are expressed at a low level, then HMGA1 and HMGA2 proteins are expressed at a high level. HMGA1 and HMGA2 target (reduce expression of) BRCA1 and ERCC1 DNA repair  genes. Thus DNA repair can be reduced, likely contributing to cancer progression.
AT hooks, that bind the minor groove of AT-rich DNA stretches in specific regions of DNA. Human neoplasias, including thyroid, prostatic, cervical, colorectal, pancreatic and ovarian carcinoma, show a strong increase of HMGA1a and HMGA1b proteins. Transgenic mice with HMGA1 targeted to lymphoid cells develop aggressive lymphoma, showing that high HMGA1 expression is not only associated with cancers, but that the HMGA1 gene can act as an oncogene to cause cancer. Baldassarre et al., showed that HMGA1 protein binds to the promoter region of DNA repair gene BRCA1 and inhibits BRCA1 promoter activity. They also showed that while only 11% of breast tumors had hypermethylation of the BRCA1 gene, 82% of aggressive breast cancers have low BRCA1 protein expression, and most of these reductions were due to chromatin remodeling by high levels of HMGA1 protein.
In 29–66% of glioblastomas, DNA repair is deficient due to epigenetic methylation of the MGMT gene, which reduces protein expression of MGMT. However, for 28% of glioblastomas, the MGMT protein is deficient but the MGMT promoter is not methylated. In the glioblastomas without methylated MGMT promoters, the level of microRNA miR-181d is inversely correlated with protein expression of MGMT and the direct target of miR-181d is the MGMT mRNA 3’UTR (the three prime untranslated region of MGMT mRNA). Thus, in 28% of glioblastomas, increased expression of miR-181d and reduced expression of DNA repair enzyme MGMT may be a causal factor.
Among 68 sporadic colon cancers with reduced expression of the DNA mismatch repair protein MLH1, most were found to be deficient due to epigenetic methylation of the CpG island of the MLH1 gene. However, up to 15% of the MLH1-deficiencies in sporadic colon cancers appeared to be due to over-expression of the microRNA miR-155, which represses MLH1 expression.
Germ line mutations in DNA repair genes cause only 2–5% of colon cancer cases. However, altered expression of microRNAs, causing DNA repair deficiencies, are frequently associated with cancers and may be an important causal factor for these cancers.
DNA damage is considered to be the primary underlying cause of cancer. If DNA repair is deficient, damage tends to accumulate in DNA. Such DNA damage can cause mutational errors during DNA replication due to error-prone translesion synthesis. Accumulated DNA damage can also cause epigenetic alterations due to errors during DNA repair. Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms).
DNA repair and cancer
Recent studies have miR-205 targeted for inhibiting the metastatic nature of breast cancer. Five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) are down regulated in tumour progression of breast cancer.
Another role for miRNA in cancers is to use their expression level as a prognostic. For example, one study on NSCLC samples found that low miR-324a levels could serve as a prognostic indicator of poor survival. Either high miR-185 or low miR-133b levels may correlate with metastasis and poor survival in colorectal cancer. Hepatocellular carcinoma cell proliferation may arise from miR-21 interaction with MAP2K3, a tumor repressor gene. Optimal treatment for cancer involves accurately identifying patients for risk-stratified therapy. Those with a rapid response to initial treatment may benefit from truncated treatment regimens, thus the need for more accurate measures of disease response. Cell-free miRNA are highly stable in blood, are overexpressed in cancer, and are quantifiable within the diagnostic laboratory. In classical Hodgkin lymphoma, plasma miR-21, miR-494, and miR-1973 are promising disease response biomarkers. Circulating miRNAs have the potential to greatly assist clinical decision making and aid interpretation of positron emission tomography combined with computerized tomography. A further advantage is they can also be performed at each consultation to assess disease response and detection of early relapse.
A novel miRNA-profiling-based screening assay for the detection of early-stage colorectal cancer has been developed and is currently in clinical trials. Early results showed that blood plasma samples collected from patients with early, resectable (Stage II) colorectal cancer could be distinguished from those of sex-and age-matched healthy volunteers. Sufficient selectivity and specificity could be achieved using small (less than 1 mL) samples of blood. The test has potential to be a cost-effective, non-invasive way to identify at-risk patients who should undergo colonoscopy.
Transgenic mice that over-express or lack specific miRNAs have provided insight into the role of small RNAs in various malignancies. Much work has also been done on the role of microRNAs in establishing and maintaining cancer stem cells that are especially resistant to chemotherapy and often responsible for relapse.
By measuring activity among 217 genes encoding miRNA, patterns of gene activity that can distinguish types of cancers can be discerned. miRNA signatures may enable classification of cancer. This will allow doctors to determine the original tissue type which spawned a cancer and to be able to target a treatment course based on the original tissue type. miRNA profiling has already been able to determine whether patients with chronic lymphocytic leukemia had slow growing or aggressive forms of the cancer.
Another study found that two types of miRNA inhibit the E2F1 protein, which regulates cell proliferation. miRNA appears to bind to messenger RNA before it can be translated to proteins that switch genes on and off.
A study of mice altered to produce excess c-Myc — a protein with mutated forms implicated in several cancers — shows that miRNA has an effect on the development of cancer. Mice that were engineered to produce a surplus of types of miRNA found in lymphoma cells developed the disease within 50 days and died two weeks later. In contrast, mice without the surplus miRNA lived over 100 days. Leukemia can be caused by the insertion of a viral genome next to the 17-92 array of microRNAs leading to increased expression of this microRNA.
The first human disease known to be associated with miRNA deregulation was chronic lymphocytic leukemia. Many miRNAs have subsequently been found to have links with various types of cancer and accordingly are sometimes referred to as "oncomirs". In malignant B cells They participate in pathways fundamental to B cell development like B cell receptor (BCR) signalling, B cell migration/adhesion, cell-cell interactions in immune niches, and the production and class-switching of immunoglobulins. MiRNAs influence B cell maturation, generation of pre-, marginal zone, follicular, B1, plasma and memory B cells.
Deletion of the miR-17~92 cluster, causes skeletal and growth defects.
A mutation in the seed region of miR-184, causes hereditary keratoconus with anterior polar cataract.
A mutation in the seed region of miR-96, causes hereditary progressive hearing loss.
Just as miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation of miRNA been associated with disease. A manually curated, publicly available database, miR2Disease, documents known relationships between miRNA dysregulation and human disease.
High-throughput quantification of miRNAs is often difficult and prone to errors, for the larger variance (compared to mRNAs) that comes with the methodological problems. mRNA-expression is therefore often analyzed as well to check for miRNA-effects in their levels (e. g. in ). To pair mRNA- and miRNA-data, databases can be used which predict miRNA-targets based on their base sequence. While this is usually done after miRNAs of interest have been detected (e. g. because of high expression levels), ideas for analysis tools that integrate mRNA- and miRNA-expression information have been proposed.
MicroRNA expression can be quantified in a two-step polymerase chain reaction process of modified RT-PCR followed by quantitative PCR. Variations of this method achieve absolute or relative quantification. miRNAs can also be hybridized to microarrays, slides or chips with probes to hundreds or thousands of miRNA targets, so that relative levels of miRNAs can be determined in different samples. MicroRNAs can be both discovered and profiled by high-throughput sequencing methods (MicroRNA Sequencing). The activity of an miRNA can be experimentally inhibited using a locked nucleic acid (LNA) oligo, a Morpholino oligo or a 2'-O-methyl RNA oligo. Additionally, a specific miRNA can be silenced by a complementary antagomir. MicroRNA maturation can be inhibited at several points by steric-blocking oligos. The miRNA target site of an mRNA transcript can also be blocked by a steric-blocking oligo. For the “in situ” detection of miRNA, LNA or Morpholino probes can be used. The locked conformation of LNA results in enhanced hybridization properties and increases sensitivity and selectivity, making it ideal for detection of short miRNA.
While researchers have focused on the study of miRNA expression in physiological and pathological processes, various technical variables related to microRNA isolation have emerged. The stability of the stored miRNA samples has often been questioned. MicroRNAs are degraded much more easily than mRNAs, partly due to their length, but also because of the ubiquitously present RNases. This makes it necessary to cool samples on ice and use RNase-free equipment whenever working with microRNAs.
Experimental detection and manipulation of miRNA
Across all species, in excess of 5000 had been identified by March 2010. Whilst short RNA sequences (50 – hundreds of base pairs) of a broadly comparable function occur in bacteria, bacteria lack true microRNAs.
.Placozoa, the only known member of the phylum Trichoplax adhaerens, which are critical to canonical microRNA biogenesis. It is the only animal thus far reported to be missing Drosha. MicroRNAs play a vital role in the regulation of gene expression in all non-ctenophore animals investigated thus far except for Pasha and Drosha appears to lack recognizable microRNAs, as well as the nuclear proteins  Mnemiopsis leidyi Focusing on the animals, the genome of  to the animals. However, the difference in how these microRNAs function and the way they are processed suggests that microRNAs arose independently in plants and animals.